Trial Profile
To evaluate the efficacy and safety of switching from Infliximab to Golimumab in patients with Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Infliximab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 02 Jan 2017 New trial record
- 26 Dec 2016 Results published in the Drugs in R and D